Nieuw-Zeeland - Engels - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - hydrochlorothiazide 25mg;  ; valsartan 160mg;  ;  ;   - film coated tablet - 25mg/160mg - active: hydrochlorothiazide 25mg   valsartan 160mg       excipient: colloidal silicon dioxide crospovidone hypromellose iron oxide black iron oxide red iron oxide yellow macrogol 8000 magnesium stearate microcrystalline cellulose purified talc purified water titanium dioxide - co-diovan is indicated for the treatment of hypertension in patients whose blood pressure is not adequately controlled by monotherapy. these fixed dose combinations should be used as second line.

Nieuw-Zeeland - Engels - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - hydrochlorothiazide 12.5mg;  ; valsartan 320mg;  ;  ;   - film coated tablet - 320 mg/12.5mg - active: hydrochlorothiazide 12.5mg   valsartan 320mg       excipient: colloidal silicon dioxide crospovidone hypromellose iron oxide black iron oxide red macrogol 4000 magnesium stearate microcrystalline cellulose purified talc titanium dioxide - co-diovan is indicated for the treatment of hypertension in patients whose blood pressure is not adequately controlled by monotherapy. these fixed dose combinations should be used as second line.

Nieuw-Zeeland - Engels - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - hydrochlorothiazide 25mg (micronized);  ; valsartan 320mg;  ;  ;   - film coated tablet - 320mg/25mg - active: hydrochlorothiazide 25mg (micronized)   valsartan 320mg       excipient: colloidal silicon dioxide crospovidone hypromellose iron oxide yellow macrogol 4000 magnesium stearate microcrystalline cellulose purified talc titanium dioxide - co-diovan is indicated for the treatment of hypertension in patients whose blood pressure is not adequately controlled by monotherapy. these fixed dose combinations should be used as second line.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - valsartan, quantity: 320 mg - tablet, film coated - excipient ingredients: crospovidone; microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; titanium dioxide; macrogol 8000; hypromellose; iron oxide yellow; iron oxide red; iron oxide black - treatment of hypertension. treatment of heart failure (nyha class ii-iv) in patients receiving usual therapy (e.g. diuretics, digitalis) who are intolerant to ace inhibitors. to improve survival following myocardial infarction in clinically stable patients with clinical or radiological evidence of left ventricular failure and/or with left ventricular systolic dysfunction (see "clinical trials").

Australië - Engels - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - valsartan, quantity: 40 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; magnesium stearate; crospovidone; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 8000; iron oxide yellow; iron oxide red; iron oxide black - treatment of hypertension. treatment of heart failure (nyha class ii-iv) in patients receiving usual therapy (e.g. diuretics, digitalis) who are intolerant to ace inhibitors. to improve survival following myocardial infarction in clinically stable patients with clinical or radiological evidence of left ventricular failure and/or with left ventricular systolic dysfunction (see "clinical trials").

Australië - Engels - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - valsartan, quantity: 160 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; crospovidone; microcrystalline cellulose; magnesium stearate; titanium dioxide; hypromellose; macrogol 8000; iron oxide yellow; iron oxide red; iron oxide black - treatment of hypertension. treatment of heart failure (nyha class ii-iv) in patients receiving usual therapy (e.g. diuretics, digitalis) who are intolerant to ace inhibitors. to improve survival following myocardial infarction in clinically stable patients with clinical or radiological evidence of left ventricular failure and/or with left ventricular systolic dysfunction (see "clinical trials").

Australië - Engels - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - valsartan, quantity: 80 mg - tablet, film coated - excipient ingredients: magnesium stearate; colloidal anhydrous silica; crospovidone; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 8000; iron oxide yellow; iron oxide red - treatment of hypertension. treatment of heart failure (nyha class ii-iv) in patients receiving usual therapy (e.g. diuretics, digitalis) who are intolerant to ace inhibitors. to improve survival following myocardial infarction in clinically stable patients with clinical or radiological evidence of left ventricular failure and/or with left ventricular systolic dysfunction (see "clinical trials").

Verenigde Staten - Engels - NLM (National Library of Medicine)

novartis pharmaceuticals corporation - valsartan (unii: 80m03yxj7i) (valsartan - unii:80m03yxj7i), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - valsartan 80 mg - diovan hct (valsartan and hydrochlorothiazide, usp) is indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including hydrochlorothiazide and the angiotensin ii receptor blocker (arb) class to which valsartan principally belongs. there are no controlled trials demonstrating risk reduction with diovan hct. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education

Verenigde Staten - Engels - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - valsartan (unii: 80m03yxj7i) (valsartan - unii:80m03yxj7i), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - valsartan 160 mg - diovan hct (valsartan and hydrochlorothiazide, usp) is indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including hydrochlorothiazide and the angiotensin ii receptor blocker (arb) class to which valsartan principally belongs. there are no controlled trials demonstrating risk reduction with diovan hct. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education

Verenigde Staten - Engels - NLM (National Library of Medicine)

dispensing solutions, inc. - valsartan (unii: 80m03yxj7i) (valsartan - unii:80m03yxj7i), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - diovan hct (valsartan and hydrochlorothiazide, usp) is indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including hydrochlorothiazide and the arb class to which valsartan principally belongs. there are no controlled trials demonstrating risk reduction with diovan hct. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national comm